Baptist Health South Florida

Scholarly Commons @ Baptist Health South Florida
All Publications
6-2-2020

Etomidate use in septic patients requiring rapid sequence
intubation
Elizabeth Osmon
Boca Raton Regional Hospital, EOsmon@brrrrh.com

Nishika Patel
Boca Ration Regional Hospital, NPatel2@baptisthealth.net

Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications
Part of the Chemicals and Drugs Commons, and the Pharmacy and Pharmaceutical Sciences
Commons

Citation
Osmon, Elizabeth and Patel, Nishika, "Etomidate use in septic patients requiring rapid sequence
intubation" (2020). All Publications. 3539.
https://scholarlycommons.baptisthealth.net/se-all-publications/3539

This Conference Lecture -- Open Access is brought to you for free and open access by Scholarly Commons @
Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator
of Scholarly Commons @ Baptist Health South Florida. For more information, please contact
Carrief@baptisthealth.net.

Etomidate use in septic patients
requiring rapid sequence intubation
Elizabeth Osmon, Pharm.D.
PGY1 Resident Pharmacist
Boca Raton Regional Hospital
Baptist Health South Florida
EOsmon@brrh.com

Disclosure Statement
The listed individuals have the following to disclose regarding
financial or personal relationships with commercial entities (or
their competitors) that may be referenced in this presentation:
• Elizabeth Osmon, Pharm.D. – Nothing to disclose
• Nishika Patel, Pharm.D., BCPS, BCCCP – Nothing to
disclose

Boca Raton Regional Hospital
•

Not-for-profit 400 bed advanced academic tertiary medical center

•

Recognized leader in:
– Cardiovascular Care
– Oncology
– Women’s Health
– Orthopedics
– Emergency Medicine
– Neurosciences

•

Predominantly elderly patient population

•

Highest ranked hospital in Palm Beach County
– Listed by U.S. News & World Report 2019-2020

•

Lynn Cancer Institute is one of the largest cancer programs in the state of Florida and
accredited by the American College of Surgeons

Presentation Objective

Identify the effect etomidate has on cortisol production

Background
During sepsis, pro-inflammatory markers stimulate the
upregulation of cortisol release
An increase in cortisol production results in metabolic,
cardiovascular, and anti-inflammatory benefits in order
to maintain homeostasis during stress
A disruption in this mechanism causes primary adrenal
insufficiency and a lack of adequate stress response

Prigent H, Maxime V, and Annane D. Science review: Mechanism of impaired adrenal function in sepsis and molecular action of glucocorticoids. Crit Care 2004;8:243-252.

Background
•

Etomidate is a short-acting, sedative hypnotic that is often used as an induction agent
for rapid sequence intubation (RSI)1

•

Etomidate inhibits the enzyme 11-β hydroxylase, which is responsible for the
conversion of 11-deoxycortisol to cortisol2

•

Reduced plasma cortisol levels have been reported with a typical induction dose (0.3
mg/kg) of etomidate1

•

Although the role of etomidate in adrenal suppression has been established, the
clinical consequences of this mechanism are controversial2
11-deoxycortisol

11-β hydroxylase

cortisol

1. Amidate (etomidate) [package insert]. Lake Forest, IL: Hospira, Inc.;2017.
2. Thompson Baastin ML, Baker SN, and Weant KA. Effects of etomidate on adrenal suppression: A review of intubated septic patients. Hosp Pharm 2014;49(2):177-183.

Literature Evaluation
Study

Design

Arms

Results

Ray, et al.1 2007
n = 159

Single-center,
retrospective

Etomidate vs. other
induction agents

Induction agent did not affect
duration (P = 0.54) or dose (P =
0.53) of vasopressor therapy

Elliot, et al.2 2012
n = 50

Single-center,
retrospective

Etomidate vs. other
induction agents

No difference in the mean dose of
vasopressor in norepinephrine
equivalents (P = 0.61)

Alday, et al.3 2014
n = 411

Multicenter,
retrospective

Etomidate vs. other
induction agents

No difference in need for
vasopressor support with etomidate
vs. non-etomidate (P = 0.88)

1. Ray DC, et al. Effect of etomidate agent on vasopressor and steroid use, and outcome in patients with septic shock. Crit Care. 2007;11:R56.
2. Elliot M, et al. Does etomidate increase vasopressor requirements in patients needing mechanical ventilation? Can J Hosp Pharm. 2012;65(4):272-276.
3. Alday NJ, et al. Effects of etomidate on vasopressor use in patients with sepsis or severe sepsis: a propensity-matched analysis. J Crit Care. 2014;29(4):517-22.

Purpose

To analyze if etomidate exhibits a dose dependent effect
on the duration of intravenous (IV) vasopressor support
and other clinical outcomes in septic patients

Study Outcomes
Primary outcome
• Duration of IV vasopressor support between low dose (≤ 0.3 mg/kg)
and high dose (> 0.3 mg/kg) etomidate
Secondary outcomes
•
•
•
•

Number of patients requiring initiation of stress dose steroids
Intensive care length of stay
Duration of mechanical ventilation
Inpatient mortality

Study Design
Methods: Retrospective chart review using an electronic medical record
(EMR)-generated report from October 21, 2017 to December 31, 2019
Inclusion Criteria
• Age ≥ 18 years
• Differential diagnosis of
sepsis or septic shock
based on provider
documentation
• Received etomidate as an
induction agent for RSI

Exclusion Criteria
• History of an adrenal
disorder
• Taking medications that
directly impact adrenal
function prior to admission

Statistical Analysis

Primary
Outcome

• Mann-Whitney U test

Secondary
Outcomes

• Descriptive statistics

272
patients
assessed

Screening

126
patients
eligible

100
patients
included
79 patients
received
low-dose

26 patients
excluded

21 patients
received
high-dose

Baseline Characteristics
Variable

Low-Dose
(n = 79)

High-Dose
(n = 21)

77

81

63 – 86.5

75 – 87

31 (39.2)

14 (66.7)

77

49.7

67.9 – 90

45.4 – 57

Age – years
Median
Interquartile range
Gender – no. (%)
Female
Weight – kg
Median
Interquartile range

Results
Primary outcome: median duration of IV vasopressor support was 32
hours vs. 50.5 hours, P = 0.0455

Median [IQR]
32 [3.25, 69]

Median [IQR]
50.5 [29.5, 112.5]

Results
Secondary Outcomes
Initiated on stress dose steroids – no. (%)

Low-Dose
(n = 79)

High-Dose
(n = 21)

24 (30.4)

6 (28.6)

5

8

3 – 12

5 – 10

4

5

2 – 9.5

4–8

27 (34.2)

5 (23.8)

Intensive care length of stay – days
Median
Interquartile range
Duration of mechanical ventilation – days
Median
Interquartile range
Inpatient mortality – no. (%)

Conclusion
There was a statistically significant difference in duration of IV
vasopressor support between the low-dose and high-dose groups
Secondary outcome results were similar between the low-dose
and high-dose groups
Despite the small sample size, the significant results of this study
warrant the need for a randomized controlled trial to be conducted

Limitations
Inconsistent use of sepsis-3 criteria among providers

Limited provider documentation

Oral vasopressor support (i.e. midodrine) was not evaluated

Small sample size

Unequal treatment group sizes
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Self-Assessment Question
Which of the following correctly describes the effect etomidate
has on cortisol production?
A. Etomidate directly binds to cortisol, which makes it inactive.
B. Etomidate inhibits the enzyme 11-β hydroxylase, which is
responsible for conversion of 11-deoxycortisol to cortisol.
C. Etomidate regulates cortisol production through a negative
feedback mechanism.
D. Etomidate does not affect cortisol production.
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